Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of malignant mesothelioma~* Unresectable or inoperable malignant mesothelioma failing after at least one prior chemotherapy regimen including platinum derivatives (cisplatin or carboplatin)~* At least one evaluable or measurable CT-lesion~* Availability for participating in the detailed follow-up of the protocol~* Signed informed consent~Exclusion Criteria:~* Patients who are candidates for surgery with curative intent~* Patient who were previously treated with anthracyclin derivatives~* Performance status \< 60 on the Karnofsky scale~* A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval)~* A history of prior HIV infection~* Polynuclear cells \< 2,000/mm³~* Platelet cells \< 100,000/mm³~* Abnormal coagulation tests (aPTT, PTT, prothrombin time) and/or decreased fibrinogen~* Serum bilirubin \>1.5 mg/100 ml~* Transaminases more than twice the normal range~* Serum creatinine \> 1.5 mg/100 ml~* Recent myocardial infarction (less than 3 months prior to date of diagnosis)~* Congestive cardiac failure (ejectional fraction of the left ventricle \< 50%) or uncontrolled cardiac arrhythmia~* Uncontrolled infectious disease~* Active epilepsy needing a specific treatment~* Concomitant treatment with IMAO, carbamazepine, mefloquine, phenobarbital, primidone, phenytoïn, lamotrigine, zidovudine~* Pregnancy or refusal to use active contraception~* A known allergy to valproate acid and/or doxorubicin~* Serious medical or psychological factors which may prevent adherence to the treatment schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).